CSF3 and breast carcinoma: The administration rate of secondary prophylaxis of G-CSF was 78.8% (108/137) in our study, which was higher than the 66.7% (14/21) of Japanese patients with breast cancer who received an epirubicin and cyclophosphamide (EC) regimen from 2014 to 2018 [14].